ShockWave Medical, Inc. (SWAV)

ShockWave Medical, Inc. (SWAV) Healthcare & Pipeline Overview

ShockWave Medical, Inc. pioneers intravascular lithotripsy (IVL) for calcified plaque modification in cardiovascular disease, offering M5, C2, and S4 catheters. With a strong 86.9% gross margin and 20.2% profit margin, the company serves interventional cardiologists, vascular surgeons, and radiologists globally, positioning it as a key player in the medical device sector.

What Is the Investment Thesis for SWAV?

ShockWave Medical presents a compelling investment thesis driven by its innovative IVL technology and strong market position in the treatment of calcified cardiovascular disease. With a high gross margin of 86.9% and a profit margin of 20.2%, the company demonstrates efficient operations and strong profitability. The aging global population and increasing prevalence of cardiovascular disease are expected to drive continued demand for ShockWave's products. Key growth catalysts include expanding indications for IVL technology, penetrating new geographic markets, and generating positive clinical data supporting the use of IVL in complex lesions. However, potential risks include competition from established medical device companies, regulatory hurdles, and the need for ongoing clinical validation to support adoption by physicians. The company's P/E ratio of 83.4 reflects investor expectations for future growth, but also highlights the importance of executing on its strategic initiatives.

Based on FMP financials and quantitative analysis

SWAV Key Highlights

• Market capitalization of $12.57B reflects strong investor confidence in ShockWave Medical's growth potential.
• Gross margin of 86.9% indicates efficient cost management and strong pricing power.
• Profit margin of 20.2% demonstrates the company's ability to translate revenue into net income.
• Beta of 0.88 suggests lower volatility compared to the overall market.
• Intravascular Lithotripsy (IVL) technology addresses a significant unmet need in treating calcified cardiovascular disease.

Who Are SWAV's Competitors?

SWAV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SWAV's Key Strengths?

• Innovative intravascular lithotripsy (IVL) technology.
• Strong clinical data supporting safety and efficacy.
• High gross margin and profit margin.
• Experienced management team.

What Are SWAV's Weaknesses?

• Reliance on a single technology platform.
• Limited product portfolio compared to larger competitors.
• High P/E ratio may indicate overvaluation.
• Dependence on regulatory approvals for new products and indications.

What Could Drive SWAV Stock Higher?

• Publication of clinical trial results evaluating IVL in complex coronary lesions (Q3 2026).
• Regulatory approval for expanded indications of IVL in peripheral artery disease (Q4 2026).
• Continued adoption of IVL technology by physicians in existing markets.
• Expansion of sales and marketing efforts in new geographic regions.
• Development and launch of next-generation IVL catheters.

What Are the Key Risks for SWAV?

• Rich valuation — a P/E of 83.4 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Competition from established medical device companies with greater resources.
• Regulatory delays or unfavorable reimbursement decisions.
• Product liability claims related to IVL technology.
• Dependence on key personnel and manufacturing facilities.
• Economic downturns affecting hospital budgets and capital spending.

What Are the Growth Opportunities for SWAV?

• Expanding Indications for IVL Technology: ShockWave Medical has the opportunity to expand the use of its IVL technology beyond its current indications in peripheral and coronary artery disease. Exploring applications in treating calcified lesions in other vascular beds, such as renal or carotid arteries, could significantly increase the addressable market. Clinical trials and regulatory approvals would be necessary to support these expanded indications, potentially unlocking a multi-billion dollar market opportunity over the next 3-5 years.
• Penetrating New Geographic Markets: ShockWave Medical can drive growth by expanding its geographic presence, particularly in emerging markets with large and underserved patient populations. Countries in Asia-Pacific, Latin America, and Eastern Europe represent significant growth opportunities. Establishing strategic partnerships with local distributors and obtaining regulatory approvals in these regions are key steps to successful market entry. This expansion could contribute substantially to revenue growth within the next 2-4 years.
• Generating Positive Clinical Data: Continued investment in clinical research to generate positive data supporting the use of IVL in complex lesions and specific patient subgroups is crucial for driving adoption by physicians. Publishing studies demonstrating the safety and efficacy of IVL compared to traditional methods can strengthen the company's competitive position and support reimbursement decisions by payers. This ongoing clinical validation is essential for long-term growth and market penetration.
• Developing Next-Generation IVL Catheters: Investing in research and development to create next-generation IVL catheters with enhanced features, such as improved deliverability, smaller profiles, or integrated imaging capabilities, can further differentiate ShockWave Medical's products from competitors. These innovations can address unmet clinical needs and expand the applicability of IVL technology to a wider range of patients and lesion types. The development and launch of new products can drive revenue growth and maintain a competitive edge.
• Strategic Acquisitions and Partnerships: ShockWave Medical could pursue strategic acquisitions or partnerships to expand its product portfolio, access new technologies, or strengthen its market position. Acquiring companies with complementary technologies or distribution networks can accelerate growth and diversify revenue streams. Collaborating with other medical device companies or research institutions can foster innovation and accelerate the development of new products and therapies. These strategic initiatives can enhance the company's long-term growth prospects.

What Opportunities Does SWAV Have?

• Expanding indications for IVL technology.
• Penetrating new geographic markets.
• Developing next-generation IVL catheters.
• Strategic acquisitions and partnerships.

What Threats Does SWAV Face?

• Competition from established medical device companies.
• Regulatory hurdles and reimbursement challenges.
• Potential for product liability claims.
• Economic downturns affecting hospital budgets.

What Are SWAV's Competitive Advantages?

• Proprietary intravascular lithotripsy (IVL) technology protected by patents.
• Strong clinical data supporting the safety and efficacy of IVL.
• Established relationships with key opinion leaders and physicians.
• High barriers to entry due to regulatory requirements and specialized manufacturing expertise.

What Does SWAV Do?

ShockWave Medical, Inc., founded in 2009 and headquartered in Santa Clara, California, is a medical device company focused on transforming the treatment of calcified cardiovascular disease through its innovative intravascular lithotripsy (IVL) technology. The company's core technology utilizes sonic pressure waves to fracture calcified plaque within arteries, facilitating easier and safer stent deployment, angioplasty, or valve replacement. This approach minimizes trauma to soft tissues, reducing complications associated with traditional methods. ShockWave Medical's product portfolio includes the M5 catheter, designed for treating above-the-knee peripheral artery disease (PAD); the C2 catheter, used in coronary artery disease interventions; and the S4 catheter, which addresses below-the-knee PAD. These catheters are integrated into a user-friendly system that allows physicians to deliver controlled lithotripsy energy directly to the calcified lesion. The company markets its products globally, targeting interventional cardiologists, vascular surgeons, and interventional radiologists. ShockWave Medical employs a direct sales force and leverages strategic distribution partnerships to reach a broad customer base. By providing a less invasive and more effective solution for treating calcified plaque, ShockWave Medical aims to improve patient outcomes and reduce healthcare costs associated with cardiovascular interventions. The company's commitment to innovation and clinical evidence has established it as a leader in the rapidly evolving field of interventional cardiology and vascular surgery.

What Products and Services Does SWAV Offer?

• Develops intravascular lithotripsy (IVL) technology.
• Commercializes IVL systems for treating calcified plaque.
• Offers M5 catheters for above-the-knee peripheral artery disease (PAD).
• Provides C2 catheters for coronary artery disease.
• Supplies S4 catheters for below-the-knee PAD.
• Serves interventional cardiologists, vascular surgeons, and interventional radiologists.
• Distributes products through sales representatives, sales managers, and distributors.

How Does SWAV Make Money?

• Develops and manufactures intravascular lithotripsy (IVL) catheters and systems.
• Sells IVL products directly to hospitals and clinics through a sales force.
• Utilizes distributors to reach international markets.
• Generates revenue from the sale of IVL catheters and systems used in cardiovascular procedures.

What Industry Does SWAV Operate In?

ShockWave Medical operates within the medical device industry, specifically targeting the cardiovascular segment. The industry is characterized by technological innovation, stringent regulatory requirements, and intense competition. The global market for cardiovascular devices is projected to grow steadily, driven by factors such as the aging population, increasing prevalence of cardiovascular disease, and advancements in minimally invasive procedures. ShockWave Medical's IVL technology offers a differentiated approach to treating calcified plaque, positioning it favorably against competitors offering traditional angioplasty and atherectomy devices. The company's focus on clinical evidence and physician training is crucial for driving adoption and gaining market share in this competitive landscape.

Who Are SWAV's Key Customers?

• Interventional cardiologists
• Vascular surgeons
• Interventional radiologists
• Hospitals and clinics performing cardiovascular procedures

How ShockWave Medical, Inc. Is Valued

ShockWave Medical, Inc. carries a market capitalization of $12.57B, placing it in the large-cap category. Relative to its peer group, SWAV's quantitative score of 60/100 is roughly in line with the peer average of 55/100.

Company Profile

ShockWave Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Santa Clara, US. The company is led by CEO Douglas E. Godshall. SWAV has traded publicly since 2019.

ROE 25%Key Financial Metrics

Return on equity for ShockWave Medical, Inc. stands at 25.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 9.4%, showing how much profit it generates from its asset base. SWAV trades at a trailing price-to-earnings ratio of 83.43, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 11.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.2%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 6/9Financial Health

ShockWave Medical, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 10.32 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project ShockWave Medical, Inc. revenue of about $1.34B for fiscal 2026, with EPS near $7.20. The estimate reflects 9 contributing analysts.

SWAV Financials

SWAV Latest News

SWAV Analyst Consensus

SWAV MoonshotScore

ShockWave Medical, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources